CN106177659A - 活力草本液 - Google Patents
活力草本液 Download PDFInfo
- Publication number
- CN106177659A CN106177659A CN201610554198.7A CN201610554198A CN106177659A CN 106177659 A CN106177659 A CN 106177659A CN 201610554198 A CN201610554198 A CN 201610554198A CN 106177659 A CN106177659 A CN 106177659A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- vigor
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 43
- 239000000843 powder Substances 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 241000411851 herbal medicine Species 0.000 claims abstract description 27
- 210000000582 semen Anatomy 0.000 claims abstract description 23
- 239000011032 tourmaline Substances 0.000 claims abstract description 23
- 229910052613 tourmaline Inorganic materials 0.000 claims abstract description 23
- 229940070527 tourmaline Drugs 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 22
- 239000000919 ceramic Substances 0.000 claims abstract description 16
- 241000208340 Araliaceae Species 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 239000009636 Huang Qi Substances 0.000 claims abstract description 13
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 13
- 239000007766 cera flava Substances 0.000 claims abstract description 12
- 239000003921 oil Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 19
- 230000036541 health Effects 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 239000000341 volatile oil Substances 0.000 claims description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 8
- 239000011630 iodine Substances 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 238000009413 insulation Methods 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000007127 saponification reaction Methods 0.000 claims description 5
- 241000345998 Calamus manan Species 0.000 claims description 3
- 240000007436 Cananga odorata Species 0.000 claims description 3
- 235000007571 Cananga odorata Nutrition 0.000 claims description 3
- 241000218645 Cedrus Species 0.000 claims description 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 3
- 240000002319 Citrus sinensis Species 0.000 claims description 3
- 240000000560 Citrus x paradisi Species 0.000 claims description 3
- 244000004281 Eucalyptus maculata Species 0.000 claims description 3
- 244000042664 Matricaria chamomilla Species 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 244000179970 Monarda didyma Species 0.000 claims description 3
- 235000010672 Monarda didyma Nutrition 0.000 claims description 3
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 235000012950 rattan cane Nutrition 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims 8
- 235000008216 herbs Nutrition 0.000 claims 2
- 235000005979 Citrus limon Nutrition 0.000 claims 1
- 244000131522 Citrus pyriformis Species 0.000 claims 1
- 239000010502 orange oil Substances 0.000 claims 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 abstract description 40
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 abstract description 10
- 229940099259 vaseline Drugs 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 75
- 230000000694 effects Effects 0.000 description 60
- 210000004369 blood Anatomy 0.000 description 40
- 239000008280 blood Substances 0.000 description 40
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 28
- 239000008103 glucose Substances 0.000 description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 235000001727 glucose Nutrition 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 210000003734 kidney Anatomy 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 235000000346 sugar Nutrition 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000002689 soil Substances 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 230000004060 metabolic process Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 description 11
- 239000011707 mineral Substances 0.000 description 11
- 235000010755 mineral Nutrition 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 210000000496 pancreas Anatomy 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 210000004153 islets of langerhan Anatomy 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 150000002304 glucoses Chemical class 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 239000004575 stone Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000051325 Glucagon Human genes 0.000 description 6
- 108060003199 Glucagon Proteins 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 6
- 229960004666 glucagon Drugs 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000011505 plaster Substances 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 206010036067 polydipsia Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- -1 volcano Magnesium Chemical compound 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 2
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 235000002710 Ilex cornuta Nutrition 0.000 description 2
- 241001310146 Ilex cornuta Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000607292 Maguireothamnus speciosus Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000009341 apiculture Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960003468 gliquidone Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000004021 humic acid Substances 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 239000002366 mineral element Substances 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 239000000712 neurohormone Substances 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 description 2
- 208000015891 sexual disease Diseases 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UXDFUVFNIAJEGM-UHFFFAOYSA-N 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1CCC1=CC(OC)=C(OC)C(OC)=C1 UXDFUVFNIAJEGM-UHFFFAOYSA-N 0.000 description 1
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000272816 Anser cygnoides Species 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000037803 Coptis deltoidea Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241001504664 Crossocheilus latius Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 244000283926 Dendrobium chrysotoxum Species 0.000 description 1
- 244000030990 Dendrobium fimbriatum Species 0.000 description 1
- 240000004638 Dendrobium nobile Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 241000005043 Lygodiaceae Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000961970 Plantago depressa Species 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229910006016 Si6O18 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241001534930 Thymelaeaceae Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000005686 electrostatic field Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000002509 fulvic acid Substances 0.000 description 1
- 229940095100 fulvic acid Drugs 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002061 histotrophic effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229950004152 insulin human Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- XMFOQHDPRMAJNU-UHFFFAOYSA-N lead(ii,iv) oxide Chemical compound O1[Pb]O[Pb]11O[Pb]O1 XMFOQHDPRMAJNU-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000010303 mechanochemical reaction Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005616 pyroelectricity Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052604 silicate mineral Inorganic materials 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002563 splenic artery Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0625—Warming the body, e.g. hyperthermia treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
活力草本液,以重量份计,至少包含如下组分:火山能量泥100份;托玛琳粉5‑10份;陶瓷粉6‑8份;松香粉1‑3份;凡士林5‑15份;精油1‑5份;蜂蜡20‑25份;中草药混合物30‑40份;所述中草药混合物中各物质及其在中草药混合物中的重量份数为:人参8‑16份、黄芪2‑10份、知母2‑10份、栀子4‑12份、石斛6‑14份、黄精4‑12份、枸杞6‑14份、葛根8‑16份、黄连10‑18份、三七18‑26份、厚朴1‑8份、仙鹤草1‑8份、虎杖2‑10份、巴戟天4‑12份、车前子8‑16份、沉香14‑22份、大豆20‑28份、金刚刺31‑39份、金樱根16‑24份、金沙藤16‑24份。
Description
技术领域
本发明涉及外用药膏领域,特别涉及一种活力草本液及其使用方法。
背景技术
金、木、水、火、土五种最基本的物质是构成世界不可缺少的元素,五种物质相互滋生,相互制约,处在不断的变化之中,这种学说对后来古代唯物主义哲学有着深远的影响。同时,也协助并指引了古代的天文学、气象学、化学、数学、音乐和医学等发展起来。我国古代医学家在长期的医学实践基础上,将阴阳五行学说广泛的运用于医学领域用以说明人类生命起源、生理现象和病理变化,指导着临床的诊断和防治,成为中医理论的重要组成部分,对中医理论体系的形成和发展产生了极为深刻的影响。
随着人们物质生活水平的提高,生活的环境质量逐渐下降,现代人所承受的压力也越来越大,糖尿病的发病率也在逐年上升。糖尿病是一种受遗传因素、环境因素及生活习惯所影响导致的一种慢性代谢性疾病。糖尿病是一组以高血糖为特征的代谢性疾病。高血糖则是由于胰岛素分泌缺陷或其生物作用受损,或两者兼有引起。糖尿病时长期存在的高血糖,导致各种组织,特别是眼、肾、心脏、血管、神经的慢性损害、功能障碍。主要原因是人体胰腺不能正常产生胰岛素(胰岛素缺乏)或身体不能正常利用胰岛素(胰岛素抵抗),导致血糖高于正常的一种综合征。糖尿病会引起多食、多饮、多尿、四肢无力或末梢神经炎,以及视网膜病变、胃肠功能紊乱、性机能障碍等症。
目前的治疗手段通常采用西药治疗,使用磺脲类药物如达美康、优降糖、美吡达、糖适平等,容易造成皮肤性过敏、瘙痒、红斑、荨麻疹、丘疹、头痛、头晕、嗜睡、视力模糊、视力震颤、身体平衡障碍,服用此药一年以上者药效降低;使用双胍类药物如美迪康、格华止、迪化糖锭等,长期使用容易导致糖尿病患者乳酸性酸中毒、消化道不良、更会对肝肾造成损伤,严重的引起加重酮症酸中毒;使用α-葡萄糖苷酶抑制剂如拜糖苹、倍欣等,主要副作用为胃肠道反应,具体表现有腹胀、胃胀、上腹部灼痛、腹泻或便秘。如长期使用则需不断加大药量,身体亦会产品抗药性;使用胰岛素如动物胰岛素、人胰岛素等,会出现血糖反应、 体重增加、屈光不正、水肿、过敏反应、注射部位皮下脂肪萎缩、胰岛素抗药性等症状。因为西药通过胃吸收,肝解毒,肾解析,副作用大,治标不治本。
糖尿病属于中医消渴的范畴。消渴是以多饮、多食、多尿、身体消瘦为特征的一种疾病。中医认为,饮食不节、情志失调、劳欲过度、素体虚弱等因素均可导致消渴。该病的病机特征是阴虚燥热,以阴虚为本,以燥热为标,且两者互为因果:燥热甚者则阴虚越甚,阴虚甚者则燥热越甚。消渴的病变部位在肺、胃和肾,而以肾脏的病变为重。如果患者肺燥阴虚,津液失于滋润,则会出现口干舌燥、烦渴多饮的上消症状;若患者胃热炽盛,腐熟水谷的能力过盛,则会出现多食易饥的中消症状;若患者肾虚精亏,不能约束小便,则会出现尿频量多、尿浊如脂膏的下消症状;若患者兼有肺燥、胃热与肾虚的因素,则会同时出现多饮、多食、多尿等症状。
糖尿病的病程较长,该病患者的病情常常日久不愈,最终会因气阴两伤而合并出现其他病变。例如,患者若肺燥阴伤,可合并肺痨等病症,若肾阴亏耗,肝失滋润,可合并雀目、内障、耳聋等病症,若燥热内炽,蕴毒成脓,可合并疮疖、痈疽等病症,若阴虚燥热,炼液为痰,痰阻经络,可合并中风偏瘫或胸痹心痛等病症。
采用中医外治疗法治疗疾病,通过“皮肤吃药”、内病外治,其毒副作用小,肝肾受损少,不伤肠胃。由于是在体表施治,现有的中医外治疗法穿透效果有限,只能渗透到皮下组织,无法深入到患病的脏腑器官,并且见效较慢。此外,市面上流通的一些膏药含有白芷、细辛、生马钱子、红丹等物质,其中白芷具有光敏性,和皮肤接触后,在光照下会引起皮肤发黑、长斑,甚至引起抽搐、高血压、孕妇流产;细辛对人体皮肤的刺激性较大,会引起火辣、麻木、过敏等症状;生马钱子具有毒性,国家明令禁止在化妆品中添加,一旦患处皮肤存在破损,会导致严重的中毒反应;红丹即四氧化三铅,接触皮肤时确实能起到杀菌杀寄生虫,治疗疱疹和痱子的效果,但是会引起铅中毒,导致腹痛、腹泻、血管痉挛和肝肾损害,长期使用会导致死亡。
发明内容
本发明所述的活力草本液是指施于人体穴位的外用泥状膏药。和现有技术相比,本发明提供的活力草本液,含有天然植物精华,不含任何对皮肤产生刺激的 物质以及铅类物质。将活力草本液涂覆于体表的胰岛部位、神阙穴、肾俞穴以及涌泉穴处,其所含有的天然植物精华能够直接渗透到脏腑,作用于患病部位,能调整阴阳,激生正气,活血降糖,滋阴生津,健脾益肾,敛气固精,调节代谢机能,纠正体内代谢紊乱,促使糖、蛋白质、脂肪等代谢恢复正常,使血糖、尿糖降至正常或接近正常,针对中医证候为气阴两虚证的糖尿病有特别好的疗效。
活力草本液,以重量份计,至少包含如下组分:
所述中草药混合物中各物质及其在中草药混合物中的重量份数为:
人参8-16份、黄芪2-10份、知母2-10份、栀子4-12份、石斛6-14份、黄精4-12份、枸杞6-14份、葛根8-16份、黄连10-18份、三七18-26份、厚朴1-8份、仙鹤草1-8份、虎杖2-10份、巴戟天4-12份、车前子8-16份、沉香14-22份、大豆20-28份、金刚刺31-39份、金樱根16-24份、金沙藤16-24份。
作为本发明的一种技术方案,所述中草药混合物中各物质及其在中草药混合物中的重量份数为:
人参10-14份、黄芪4-8份、知母4-8份、栀子6-10份、石斛8-12份、黄精6-10份、枸杞8-12份、葛根10-14份、黄连12-16份、三七20-24份、厚朴2-6份、仙鹤草2-6份、虎杖4-8份、巴戟天6-10份、车前子10-14份、沉香16-20份、大豆22-26份、金刚刺33-37份、金樱根18-22份、金沙藤18-22份。
作为本发明的一种技术方案,所述中草药混合物中各物质及其在中草药混合物中的重量份数为:
人参12份、黄芪6份、知母6份、栀子8份、石斛10份、黄精8份、枸杞10份、葛根12份、黄连14份、三七22份、厚朴4份、仙鹤草4份、虎杖6份、 巴戟天8份、车前子12份、沉香18份、大豆24份、金刚刺35份、金樱根20份、金沙藤20份。
作为本发明的一种技术方案,所述托玛琳粉的粒径为200-10000目。
作为本发明的一种技术方案,所述陶瓷粉的粒径为80-1250目。
作为本发明的一种技术方案,所述精油选自艾叶精油、薰衣草精油、玫瑰精油、甜橙精油、迷迭香精油、佛手柑精油、尤加利精油、雪松精油、葡萄柚精油、柠檬精油、依兰精油、洋甘菊精油中的至少一种。
作为本发明的一种技术方案,所述蜂蜡的酸值为4-9mgKOH/g,碘值为6-13g/100g,皂化值为75-100mg/g。
一种如上所述的活力草本液的使用方法,包括如下步骤:
(1)将所述活力草本液加热;
(2)将病灶处皮肤清洁干净,用灸油推按,热敷病灶处皮肤,待活力草本液温度降至50℃以下后,涂覆于病灶处皮肤表面;
(3)盖上塑料薄膜保温,30-75min后将人体皮肤表面洗净。
作为本发明的一种技术方案,所述加热为微波加热,加热时间为90-210s。
如上所述的活力草本液在化妆品、外敷药、外敷保健品领域中的应用。
具体实施方式
除非另有限定,本文使用的所有技术以及科学术语具有与本发明所属领域普通技术人员通常理解的相同的含义。当存在矛盾时,以本说明书中的定义为准。
当量、浓度、或者其它值或参数以范围、优选范围、或一系列上限优选值和下限优选值限定的范围表示时,这应当被理解为具体公开了由任何范围上限或优选值与任何范围下限或优选值的任一配对所形成的所有范围,而不论该范围是否单独公开了。例如,当公开了范围“1至5”时,所描述的范围应被解释为包括范围“1至4”、“1至3”、“1-2”、“1-2和4-5”、“1-3和5”等。当数值范围在本文中被描述时,除非另外说明,否则该范围意图包括其端值和在该范围内的所有整数和分数。
本发明所述的活力草本液是指施于人体穴位的外用泥状膏药。
活力草本液,以重量份计,至少包含如下组分:
火山能量泥
火山能量泥是一种矿物泥,以火山能量泥为载体养生,能最好的利用其能量,生阳祛邪,补阳扶正,而且环保,并能补充人体所缺少的许多稀有元素,如钾、锌、硒、锶、钛、钴、钙、钡、铁、磷、镁、钠等。火山能量泥疏松多孔,其比表面积比炭要大得多,具有超强的吸附能力,能够有效吸走毛孔内的污垢。火山能量泥采用天然取材,无毒而不过敏,也不会粘在身上,不会有拔出皮肤毛发所带来的痛苦。火山能量泥与人体皮肤接触后会逐渐散发热量,这种热量柔和并且有渗透力,持续时间能达到40min以上。
本发明所述的火山能量泥可以选自产地加拿大或中国的天然绿石泥,含有铜、硒、钼、硅、铝、镁、钙、铁、钛、硫、钾等微量元素,在人体皮肤表面有利于抗菌、排毒和新陈代谢。绿石泥是一种天然生物土壤,它是数万年以前由深海中富含各种生物的海泥,经剧烈造山运动,由海底上升而露出海洋的。经长期与二氧化碳反应,形成极其罕见的弱碱性土壤并风化成极其微细的粉末;各种海底生物成份和多种矿物质,使其天然地呈现出一种绿色。它含有丰富的矿物质,为人体肌肤所必须,绿石泥特有的孔状结构,具有超凡的吸附能力,能彻底清除紧肤深层污垢及油脂,使皮肤保持充分的清洁状态,以进一步吸收其它营养护肤成份。特有负电荷和与皮肤天然pH相同的酸碱值能激发细胞的活力,促进皮肤新陈代谢。有排毒及活肤的功效,可以有效地软化阻塞在毛孔的硬化皮脂。
本发明所述的火山能量泥可以选自产地美国的天然火山玫瑰泥,外观为粉红色极细粉末。玫瑰红泥含有多种矿物元素和多种生物活性效应的稀土元素,特别含有能与人体内许多的高分子蛋白核酸等相互促进产生活性酶,超强的送氧能力,加快肌肤吸收养分,促进肌肤对矿物元素的吸收,滋养肌肤,使肌肤白里透红, 滋润有光泽,还能杀灭有害细菌收紧肌肤,保持肌肤活力;有效消除电磁辐射对人体健康的威胁,保持自然原生态。
本发明所述的火山能量泥可以选自产地美国的天然火山白石泥,外观为白色极细粉末。天然白石泥具微酸性质,pH约5.5左右,非常适合敏感性肌肤使用,对控油有一定的效果,也提供微量元素,可以有效地软化阻塞在毛孔的硬化皮脂,让人体毛孔畅通,改善过敏肤质。
本发明所述的火山能量泥可以选自产地加拿大的死海黑泥。死海黑泥含有丰富的矿物质,使用肌肤上,可以清除衰老的细胞以及预防毛细孔阻塞,能深层清洁毛孔内脏污,使肌肤变得细致光滑,特别适合油性肌肤使用。
本发明所述的火山能量泥可以选自产地加拿大的万年冰河泥。冰河泥乃冰河时期湖底或海口的冰河沉淀物,经过数百万年的地质演变、压缩、净化而成今日之富含矿物质之天然冰河泥。万年冰河泥是大自然累积至少400万年而成,含有30多种天然矿物质。万年冰河泥由一种奇妙的角质体构成,具有离子渗透性能,敷在皮肤上能增加血液循环,促进新陈代谢,同时能有效的去除无用的皮肤角质,滋养皮肤,增进细胞氧化,从而使皮肤容光焕发,质地细腻,富有光泽弹性的皮肤,恢复青春活力。
本发明所述的火山能量泥可以选自产地美国的海藻矿泥。其包含萃取于海沙的碾碎微粒细壳和氧化铝结晶,都是高效的去角质成份。硅藻土可增加皮肤亮泽,氧化铝结晶更是常被皮肤科医师用于微晶磨皮疗程,能够彻底安全地清除表皮衰老细胞,进一步提升表皮层的细胞更新。持续使用一段时间,可淡化皱纹和纹路,使肤色明亮透明和均匀。也可以更新皮肤质感,缩小毛孔及减少皮肤皱纹,皮肤变的分外幼滑柔软。
本发明所述的火山能量泥可以来自于FANTEXI AK-001、FANTEXI AK-002、FANTEXIAK-003、FANTEXI AK-004、FANTEXI AK-005、FANTEXI AK-008,也可以来自其它的品牌型号。
火山能量泥能够深度清洁皮肤,因为其中的矿物质,能渗入皮肤角质层,使老化的角质细胞分离、脱落,促进角质细胞的新陈代谢;而且其中的矿物盐,在渗入皮肤的过程中能起到消炎、杀菌效果;火山能量泥的高粘度性和吸附性,可使隐藏在毛囊深处的污垢和多余油脂被吸出。三重功效同时作用,使皮肤实现真 正的清洁。
当火山能量泥涂抹于皮肤时,角质层的水合作用明显增加。火山能量泥中高含量的镁、钙离子,在泥土的高渗透压作用下,能渗入皮下组织,刺激皮肤胶原蛋白的合成,增强皮肤的锁水功能。其中的天然维生素E和氨基酸,能直接被皮肤吸收,滋润和营养皮肤。
火山能量泥的温热效应能促使全身皮肤的毛孔张开,汗腺分泌增加,体内毒素随汗液排出体外。其中高浓度的矿物盐,可刺激皮下毛细血管扩张,血液循环加速,皮下代谢产物及毒素随血液和汗液而经肾脏和皮肤排泄。火山能量泥中水分蒸发过程中引起的皮肤紧缩能促进皮下淋巴液的回流,增强淋巴排毒的功效。因为火山能量泥在身上逐渐干裂会让身体紧收,干裂时更具吸附功能,它不仅吸附皮肤表层的角质,还会张开毛孔吸附出里边的黑头,毒素,改善皮肤病和暗疮。最后当张开毛孔后再进行加热出汗将更多毒素排出体内。而皮肤也会表现为美白,细腻,嫩滑,倍感健康。这收紧后再放松的过程是很好的理疗和养生效果。
火山能量泥中高浓度的矿物质能增进皮肤的氧合速率,加速皮肤新陈代谢和强化皮肤细胞膜表层,改善皮肤呼吸及血液循环,腐殖酸和活性黄腐酸具有防止紫外线和抑制黑色素酶产生的功能,使皮肤光滑白嫩。蛋白质和氨基酸能促进皮下网状支撑结构更富弹性,增强皮肤的保湿和抗皱功能;维生素E具有很强的抗氧化功能,能清除体内产生的自由基。
人体衰老的主要原因是人体内活性氧自由基引起。所谓自由基是一种带有不成对负电子的分子、离子或原子,它能作用于细胞膜及血液中的脂类物质形成脂质过氧化物,这些过氧化物沉积在细胞膜上,使生物体丧失功能,造成细胞活力下降、机体衰老。而火山能量泥中含有的矿物质,如锌、硒、铜、锰、铁等,和维生素E、β-胡萝卜素、腐殖酸,这些都是分子量很低且易被人体吸收的天然抗氧化剂,能有效防止机体免受自由基的侵害,提高人体内SOD酶的活性,从而达到延缓机体衰老的目的。维生素E、微量元素硅等具有营养皮肤、保持皮肤水分、增加皮下胶原蛋白含量、防止色素沉着等功效,从而达到心理状态的年轻和充满活力。火山能量泥能显著增强SOD及GSH生物酶的活力。同时能明显增加皮肤中的胶原蛋白含量,具有延缓皮肤衰老的功效。
阴阳是宇宙间的一般规律,是一切事物的纲纪,万物变化的起源,生死的根 本,有很大道理在乎其中。凡医治疾病,必须求得病情变化的根本,而道理也不外乎阴阳二字。环境污染,电磁辐射都是导致阴阳失衡的罪魁祸首。阳气盛在现代人中表现为:热性病症,如性能力下降,不育症,腰酸背疼,烦躁,胸闷,肾虚火,四肢无力,紧张,过度亢奋等,热病到达极至也会表现为寒病现象;阴气盛则表现为:不孕症,月经不调,大喜,大怒,身体浮肿,疼痛,伤寒,咳嗽等,寒病到达极至也会表现为热病现象。火山能量泥是天地精华,日月灵气,万物生长发育之根本,遇阳则阴,遇阴则阳,用释放能量和吸收浊气的方式协调身体的阴阳平衡,维持身体健康。现代人的生存环境中,最为严重就是五行缺土,土运不及,风气因而流行,土气失却生化之能力,人们的疾病多见消化不良的泄泻,上吐下泻的霍乱,身体重,腹中痛,筋骨动摇,肌肉跳动酸疼,时常容易发怒等。在人体应在脾脏,其病所内在心腹,外在肌肉四肢。火山能量泥的功效就是用于补充五行之土,排入侵体内之毒,以遵循维持五行变化规律,让身体各部合理运行,达到天人相应的养生之道。
托玛琳粉
托玛琳也被称为碧玺,是一种含有硼、铝、钠、铁、锂的硅酸盐矿物。其化学结构可以表示为XY3Z6(T6O18)(BO3)3V3W,根据产地和矿区的不同化学式会存在差异,其中X一般为Na或Ca,或者是K,或者是空缺。Y位置一般是如Li+、Mg2+、Fe2+、Mn2+、Al3+、Cr3+、V3+、Fe3+、Ti4+等的多价态阳离子。Z位置主要是三价阳离子,如Al3+、Fe3+、Cr3+、V3+等,也可以是二价阳离子如Mg2+、Fe2+等。T位置一般是Si,但是根据产地的不同也可能是Al或B。当这些不确定元素位置被Cr、V、Ti、Fe、Cu等元素替代时,托玛琳就呈现出各种不同的颜色。
托玛琳具有[Si6O18]复三方环结构,属三方晶系。托玛琳具有压电性和热电性,在温度和压力变化的情况下,托玛琳的晶格之间能够产生1×106eV的电势差,这个静电场能够使空气电离,被击中的电子附着于相近的水分子和氧分子,使它们转化为空气负离子。托玛琳粉的比表面积非常大,能够产生大量负氧离子,对细胞的渗透性也更好,产生的负氧离子能够清除人体内的自由基,能够延缓衰老。托玛琳另外一个优点是能够辐射出波长为4-14μm的电磁波,和人体辐射出的电磁波频率范围匹配。电磁波频率相匹配时将会产生共振,会使人体内的水分子活化,作用于皮肤表面时能够使其它高分子量的营养成分可以进入细胞内部。
作为本发明的一种技术方案,所述托玛琳粉的粒径为200-10000目。
托玛琳粉的制法可以采用机械化学法,分为干法和湿法。干法制备的粒径分布宽,不均匀,能耗高,湿法制备的粒径分布均匀、容易控制,但是需要经过干燥、分散处理。可以将托玛琳分体用气流磨粉碎至1μm,再用湿法研磨,液相介质采用去离子水、正丁醇、乙醇,得到浆体,加入研磨介质(如粒径为1-3mm的氧化锆球)后研磨一定时间,之后进行干燥和分散处理。研磨时间约2h,浆体中固体的质量和液体的体积比约1:1,固体较多时会使浆体粘度增加,导致磨机无法顺利研磨,固体较少时得到托玛琳的粒径较大。液相介质的选择也会影响粒径大小,托玛琳属于极性颗粒,优选极性介质。以水作为液相介质时样品的粘度较大,流动性较差。以正丁醇、乙醇为液相介质的样品的粘度低、流动性好。
所述托玛琳粉可以购买自灵寿县润石矿物粉体厂、杭州赢造科技有限公司、青岛海纳微粉工程有限公司、青岛东鑛科技开发有限公司,也可以购买自其它品牌。
以火山能量泥为100重量份计,所述托玛琳粉为5-10重量份。
陶瓷粉
本发明所述陶瓷粉是指远红外陶瓷粉,呈白色粉末状,粒径为80-1250目。所述陶瓷粉需要经过处理,所述处理为置于灭菌柜内在160℃下干热灭菌1h,取出冷却后待用。
所述陶瓷粉以能够辐射出比正常物体更多的远红外线,而且红外辐射率更高。当它吸收外界的热能后,能释放出波长为4-14μm的远红外线,激活了生物大分子的活性。使生物体的分子能够被激发而处于较高振动状态。这样使激活了核酸蛋白质等生物大水分子的活性,从而发挥了生物大分子调节机体代谢、免疫等活动的功能,有利于机能的恢复和平衡,达到防病治病的目的。促进和改善血液循环。远红外作用于皮肤后,大部分能量被皮肤所吸收,被吸收的能量转化为热能,引起皮温升高,刺激皮肤内热感觉器,通过丘脑反射,使血管扩张,血液循环加快。另一方面由于热作用,引起血管活性物质的释放,血管张力低,浅小动脉、浅毛细管和浅静脉扩张,血液循环得以改善,增强新陈代谢。通过远红外热效应、可以增加细胞的活力,调整神经液机体,使体内外的物质交换处于平稳状态。具有消炎、消肿功能。远红外的热作用通过神经液的回答反应,激活了免疫细胞功 能,加强了白细胞和网状内皮细胞的吞噬功能,达到消炎抑菌的目的。增强了组织营养、活跃了组织代谢、提高了细胞供氧量,加强了细胞再生能力、改善了病区的供血氧状态、控制了炎症的发展并使其局限化,加速了病灶修复。远红外的热效应,改善了微循环、建立了侧枝循环、调节了离子的深度、促进了有毒物质的代谢、废物的排泄、加速了渗出物质的吸收、使炎症水肿消退。
陶瓷粉发源于土,属于土行,由于“火生土”,经过处理的陶瓷粉不仅具有以上效果,还可以增强火山能量泥的特性,使效果更加显著。
所述陶瓷粉可以购买自天津鸿雁天山石业纳米技术有限公司、郑州亚申化工产品有限公司、郑州康菲化工有限公司、郑州冠达化工产品有限公司,也可以购买自其它品牌。
以火山能量泥为100重量份计,所述陶瓷粉为6-8重量份。
松香粉
松香粉是由松香经过筛选、过滤、烘干、筛选、研磨、筛选等工艺制得,粒径为800-2000目。松香是以松树松脂为原料,通过不同的加工方式得到的非挥发性天然树脂。味苦甘,性温,具有祛风燥湿,排脓拔毒,生肌止痛的功效。
所述松香粉可以购买自亳州市鉴政贸易有限公司、亳州市鑫海药业销售有限公司、安国市汇安中药材有限公司、安国市金泰药材行,也可以购买自其它品牌。
以火山能量泥为100重量份计,所述松香粉为1-3重量份。
作为本发明的一种技术方案,所述凡士林为医用凡士林,为白色无臭膏状物。
所述凡士林可购买自郑州宏播利化工产品有限公司、郑州长兴化工原料有限公司,也可以购买自其它品牌。
以火山能量泥为100重量份计,所述凡士林为5-15重量份。
作为本发明的一种技术方案,所述精油选自艾叶精油、薰衣草精油、玫瑰精油、甜橙精油、迷迭香精油、佛手柑精油、尤加利精油、雪松精油、葡萄柚精油、柠檬精油、依兰精油、洋甘菊精油中的一种。
所述精油可以购买自广州芳道化妆品科技有限公司、广州果漾生物科技有限公司、广州汉佰丝日化科技发展有限公司、广州雅至化妆品有限公司,也可以购买自其它品牌。
以火山能量泥为100重量份计,所述精油为1-5重量份。
蜂蜡是工蜂腹部下面四对蜡腺分泌的物质。其主要成分有:酸类、游离脂肪酸、游离脂肪醇和碳水化合物。此外,还有类胡萝卜素、维生素A、芳香物质。
作为本发明的一种技术方案,所述蜂蜡的酸值为4-9mgKOH/g,碘值为6-13g/100g,皂化值为75-100mg/g。
酸值,指中和脂肪、脂肪油或其他类似物质1克中含有的游离脂肪酸所需氢氧化钾的重量(毫克数)。
碘值表示有机化合物中不饱和程度的一种指标。指100g物质中所能吸收(加成)碘的克数。
作为本发明优选的一种技术方案,所述蜂蜡的碘值为11-13g/100g。
皂化值的定义是皂化1克样品所需氢氧化钾的毫克数。
所述蜂蜡可以购买自广州汉佰丝日化科技发展有限公司、广州市杰禾蜂业有限公司、山东博康蜂业有限公司,也可以购买自其它品牌。
以火山能量泥为100重量份计,所述蜂蜡为20-25重量份。
中草药混合物
作为本发明的一种技术方案,所述中草药混合物中各物质及其在中草药混合物中的重量份数为:
人参8-16份、黄芪2-10份、知母2-10份、栀子4-12份、石斛6-14份、黄精4-12份、枸杞6-14份、葛根8-16份、黄连10-18份、三七18-26份、厚朴1-8份、仙鹤草1-8份、虎杖2-10份、巴戟天4-12份、车前子8-16份、沉香14-22份、大豆20-28份、金刚刺31-39份、金樱根16-24份、金沙藤16-24份。
作为本发明优选的一种技术方案,所述中草药混合物中各物质及其在中草药混合物中的重量份数为:
人参10-14份、黄芪4-8份、知母4-8份、栀子6-10份、石斛8-12份、黄精6-10份、枸杞8-12份、葛根10-14份、黄连12-16份、三七20-24份、厚朴2-6份、仙鹤草2-6份、虎杖4-8份、巴戟天6-10份、车前子10-14份、沉香16-20份、大豆22-26份、金刚刺33-37份、金樱根18-22份、金沙藤18-22份。
作为本发明优选的一种技术方案,所述中草药混合物中各物质及其在中草药混合物中的重量份数为:
人参12份、黄芪6份、知母6份、栀子8份、石斛10份、黄精8份、枸杞 10份、葛根12份、黄连14份、三七22份、厚朴4份、仙鹤草4份、虎杖6份、巴戟天8份、车前子12份、沉香18份、大豆24份、金刚刺35份、金樱根20份、金沙藤20份。
人参为五加科植物人参的干燥根。味甘、微苦,性平,具有大补元气,复脉固脱,补脾益肺,生津安神的功效。
黄芪为豆科植物蒙古黄芪或膜荚黄芪的干燥根。味甘,性温,具有补气固表,利尿托毒,排脓,敛疮生肌的功效。
知母为百合科植物知母的干燥根茎。味苦、甘,性寒,具有清热泻火,生津润燥的功效。
桅子为茜草科植物栀子的果实。味苦,性寒,具有泻火除烦,清热利湿,凉血解毒,消肿止痛的功效。
石斛为兰科植物金钗石斛、鼓槌石斛或流苏石斛的栽培品及其同属植物近似种的新鲜或干燥茎。味甘,性微寒。具有益胃生津,滋阴清热的功效。
黄精为百合科植物滇黄精、黄精或多花黄精的干燥根茎。味甘,性平,具有补气养阴,健脾,润肺,益肾的功效。
枸杞为茄科植物宁夏枸杞的干燥成熟果实。味甘,性平,具有滋补肝肾,益精明目的功效。
葛根为豆科植物野葛或甘葛藤的干燥根。味甘、辛,性凉,具有解肌退热,生津,透疹,升阳止泻的功效。
黄连为毛茛科植物黄连、三角叶黄连或云连的干燥根茎。味苦,性寒,具有清热燥湿,泻火解毒的功效。
三七为五加科植物三七的干燥根。味甘、微苦,性温,具有散瘀止血,消肿定痛的功效。
厚朴为木兰科植物厚或凹叶厚朴的干燥干皮、根皮及枝皮。味苦、辛,性温,具有燥湿消痰,下气除满的功效。
仙鹤草为蔷薇科植物龙牙草的干燥地上部分。味苦,性平,具有收敛止血,截疟,止痢,解毒的功效。
虎杖为蓼科植物虎杖的干燥根茎和根。味微苦,性微寒,具有利湿退黄,清热解毒,散瘀止痛,止咳化痰的功效。
巴戟天为茜草科植物巴戟天的干燥根。味甘、辛,性微温,具有补肾阳,强筋骨,祛风湿的功效。
车前子为车前科植物车前或平车前的干燥成熟种子。味甘,性微寒,具有清热利尿,渗湿通淋,明目,祛痰的功效。
沉香为瑞香科植物白木香含有树脂的木材。味辛、苦,性微温,具有行气止痛,温中止呕,纳气平喘的功效。
大豆为豆科植物大豆的种皮黑色的种子。具有活血利水,祛风解毒,健脾益肾的功效。
金刚刺为百合科植物菝葜的根茎。味苦辛、性平,具有除风湿,活血,解毒,镇惊息风,抗癌的功效。
金樱根为植物金樱子的根或根皮。味酸,性平,具有固精涩肠的功效。
金沙藤为海金沙科多年生攀援蕨类植物海金沙的成熟孢子。味甘,性寒,具有清热解毒,利水通淋的功效。
以火山能量泥为100重量份计,所述中草药混合物为30-40重量份。
作为本发明的一种技术方案,所述金刚刺、金樱根和金沙藤的重量比为1.5:1:1。
所述中草药混合物由其中各个组分经过挑选、漂洗、烘干或晾干后,混合粉碎制成细粉,过筛后得到。
在治疗糖尿病的配方中很少用到金刚刺、金樱根和金沙藤,金刚刺、金樱根和金沙藤多用于清热解毒、抗菌消炎、利湿通淋、补虚益肾,所述中草药混合物中按照一定重量比加入金刚刺、金樱根和金沙藤具有调节胰岛素和胰高血糖素的作用,能够预防蛋白质非酶糖化,结合人参和三七,使药效更加显著。在抑制体内胆固醇合成、改善脂质代谢的同时,增加胰岛素的敏感性。也能保护肾脏功能,减轻肾小球硬化症的严重程度,从而预防和改善糖尿病性肾病。火山能量泥、托玛琳粉、陶瓷粉不仅仅是作为载体向人体内输送营养活性成分,更能向人体补充微量元素,通过其抗脂质过氧化物的作用而减少动脉硬化、血栓形成及时血管壁的损伤,以预防和延缓血管病变的进展,有效地抑制血管胶原糖化及降低微血管的脆性和渗透性。
本发明还提供一种活力草本液的制备方法:首先取火山能量泥100重量份, 然后加入托玛琳粉5-10重量份、陶瓷粉6-8重量份、松香粉1-3重量份,再加入凡士林5-15重量份、精油1-5重量份、蜂蜡20-25重量份,最后取中草药混合物30-40重量份一同加入,混合均匀,即得。
本发明所采用的火山能量泥、托玛琳粉、陶瓷粉、松香粉、凡士林、精油、蜂蜡以及各类中草药都要经过消毒杀菌处理,消毒杀菌的方法是本领域技术人员通常采用的那些,只要使各组分达到与皮肤接触的安全标准,同时不会破坏其中的活性成分即可。
一种如上所述的活力草本液的使用方法,包括如下步骤:
(1)将所述活力草本液加热;
(2)将病灶处皮肤清洁干净,用灸油推按,热敷病灶处皮肤,待活力草本液温度降至50℃以下后,涂覆于病灶处皮肤表面;
(3)盖上塑料薄膜保温,30-75min后将人体皮肤表面洗净。
所述加热为采用烘、烤、蒸、微波等方法,以热传导、热对流、热辐射的方式加热。
保温可以采用塑料薄膜,也可以采用其它任何可以选用的材料覆盖。
作为本发明的一种技术方案,所述方法的步骤(2)中将活力草本液涂覆于体表的胰岛部位、神阙穴、肾俞穴以及涌泉穴处。
作为本发明的一种技术方案,所述加热为微波加热,加热时间为90-210s。
作为本发明一种优选的技术方案,一种如上所述的活力草本液的使用方法,包括如下步骤:
(1)将所述活力草本液使用微波加热,加热时间为90-210s;
(2)将病灶处皮肤清洁干净,用灸油推按,热敷病灶处皮肤,待活力草本液温度降至50℃以下后,涂覆于体表的胰岛部位、神阙穴、肾俞穴以及涌泉穴处;
(3)盖上塑料薄膜保温,30-75min后将人体皮肤表面洗净。
温度过高或者时间过长时,会使活力草本液中的活性成分失效。温度过低或时间过短时,活力草本液中的活性成分无法完全被激发。
如上所述的活力草本液在化妆品、外敷药、外敷保健品领域中的应用。
胰乃脾之副脏,《难经》曰:“脾有散膏半斤”,“散膏”即为胰,说明了脾和 胰密切相关。脾胰五行属土,胰尾部的A细胞分泌胰高血糖素,胰高血糖素类似脾的生化功能,如脾味甘,甘能补。糖是人体必需的营养物质,表面A细胞分泌胰高血糖素,使血中养分充足,以供细胞所需,和“脾为生化之源”相吻合。胰尾部的动脉正好与脾动脉相连通。说明了A细胞不论是位置还是功能,都与脾的生化功能相吻合。B细胞在胰的中央部位,主要分泌胰岛素,其功能是促进糖及蛋白质的合成。胰岛素充足,糖、蛋白质等合成增多,人体则强壮发胖,和“脾胃俱旺,则能食多胖”相吻合。根据阴阳五行理论,分解为阳,合成为阴。A受体兴奋,使糖原分解加快,血糖(胰高血糖素)升高,类似胰高血糖素属于脾土的阳土范畴。B受体兴奋促进糖原合成(胰岛素分泌增加),类似胰岛素属于脾土的阴土范畴。
本发明中提供的活力草本液中火山能量泥、托玛琳粉、陶瓷粉均为土行,按照本发明提供的含量比例组合使用,能够大幅提高中草药混合物在体表的渗透率,不局限于渗透到皮下,更能直接渗透到腑脏。本申请发明人经过三代人共六十多年付出大量创造性劳动的潜心研究,意想不到的发现,采用本发明所述的活力草本液及使用方法,将活力草本液涂覆于体表的胰岛部位、神阙穴、肾俞穴以及涌泉穴处,其所含有的天然植物精华能够直接渗透到脏腑,作用于患病部位,可激活惰性胰岛素,使其恢复活性,平稳降低血糖;也可保护胰岛细胞,抑制胰岛衰竭。使可参与糖代谢的胰岛素增多,胰岛不必像以前那样分泌过多的胰岛素,胰岛负担减轻,获得必要的休整,进而起到保护胰岛,抑制胰岛衰竭的作用;也可减轻化学药物依赖,胰岛获得休整,现有胰岛功能逐步恢复,自身对血糖调节能力增强,相应减轻了人体对药物的依赖,在此基础上患者可减少化学药物的用量和品种,以降低药物对身体的损伤。本发明提供的活力草本液能纠正三大代谢紊乱,阻止并发症的产生。提高血糖的转化与利用能力,不仅可有效改善代谢紊乱,而且对脂肪、蛋白质代谢紊乱也能起到积极的调节作用。缩短了治疗期,克服了传统疗法长期服药的弊端,打破传统中药无法快速降糖的说法,针对气阴两虚证所引起的糖尿病有非常好的效果。本发明提供的方法简单易行、舒适安全,适合患者自己操作,坚持使用半年就可以明显降低血糖,常年使用可以有效控制血糖、延年益寿。本发明人特将此配方公诸于世,以惠世人。
下面通过具体实施例来进一步说明本发明的实施方式,若没有特殊说明,则 均来源于商业购买。
A1天然绿石泥
A2天然火山玫瑰泥
A3天然火山白石泥
B托玛琳粉
C陶瓷粉
D松香粉
E凡士林
F艾叶精油
G1蜂蜡碘值6.7g/100g
G2蜂蜡碘值12.4g/100g
H中草药混合物(重量份)
H1 | H2 | H3 | H4 | H5 | H6 | |
人参 | 12 | 10 | 14 | 12 | 0 | 12 |
黄芪 | 6 | 4 | 8 | 6 | 6 | 6 |
知母 | 6 | 4 | 8 | 6 | 0 | 6 |
栀子 | 8 | 6 | 10 | 8 | 8 | 8 |
石斛 | 10 | 8 | 12 | 10 | 10 | 10 |
黄精 | 8 | 6 | 10 | 8 | 8 | 8 |
枸杞 | 10 | 8 | 12 | 10 | 10 | 10 |
葛根 | 12 | 10 | 14 | 12 | 12 | 12 |
黄连 | 14 | 12 | 16 | 14 | 14 | 14 |
三七 | 22 | 20 | 24 | 22 | 0 | 22 |
厚朴 | 4 | 2 | 6 | 4 | 4 | 4 |
仙鹤草 | 4 | 2 | 6 | 4 | 0 | 4 |
虎杖 | 6 | 4 | 8 | 6 | 6 | 6 |
巴戟天 | 8 | 6 | 10 | 8 | 8 | 8 |
车前子 | 12 | 10 | 14 | 12 | 12 | 12 |
沉香 | 18 | 16 | 20 | 18 | 18 | 18 |
大豆 | 24 | 22 | 26 | 24 | 24 | 24 |
金刚刺 | 35 | 35 | 35 | 0 | 35 | 31 |
金樱根 | 20 | 20 | 20 | 0 | 20 | 24 |
金沙藤 | 20 | 20 | 20 | 0 | 20 | 24 |
实施例
对比例8
采用购买的“糖尿通泥灸”。
临床资料证明了本发明的显著功效,具体临床资料如下:
一、诊断标准
1.西医诊断标准
(1)糖尿病,空腹血糖(FPG)≥7.0mmol/L(126mg/dl);或糖耐量试验(OGTT)中服糖后2小时血糖(2HPG)≥11.1mmol/L(200mg/dl);或随机血糖≥11.1mmol/L(200mg/dl)。
注:a.以上为静脉血浆测量值。如毛细血管全血测量值,则空腹血糖≥6.1mmol/L(110mg/dl),其它标准相同。
b.症状不典型者,临床诊断必须经另一天的重复试验所证实。
(2)糖耐量损害(IGT),空腹血糖<7.0mmol/L(126mg/dl),及糖耐量试验中服糖后2小时血糖≥7.8mmol/L(140mg/dl)。
注:以上为静脉血浆测量值。如毛细血管全血测量值,则空腹血糖≥6.1mmol/L(110mg/dl),其它标准相同。
(3)空腹血糖损害(IFG),6.1mmol/L(110mg/dl)≤空腹血糖<7.0mmol/L(126mg/dl),糖耐量试验中服糖后2小时血糖<7.8mmol/L(140mg/dl)。
注:以上为静脉血浆测量值。如毛细血管全血测量值,则5.6mmol/L(100mg/dl)≤空腹血糖<7.0mmol/L(126mg/dl),其它标准相同。
2.中医证候诊断标准
(1)证候
气阴两虚证
主症:咽干口燥,倦怠乏力。
次症:多食易饥,口渴喜饮,气短懒言,五心烦热,心悸失眠,溲赤便秘。
舌脉:舌红少津液,苔薄或花剥,脉细数无力,或细而弦。
二、选择病例标准
1.纳入病例标准
凡符合诊断标准者,可纳入实验选择病例。
2.排除病例标准
(1)年龄18岁以下或65岁以上,准备妊娠或已妊娠或哺乳期妇女,过敏体质者。
(2)不愿意合作者(指不能配合饮食控制或不能按规定用药而影响疗效者)及精神病患者。
(3)合并有其他严重原发性疾病者。
(4)近1月内有糖尿病酮症酸中毒等急性代谢紊乱以及合并感染者。
3.剔除标准
(1)不符合纳入标准者。
(2)观察治疗期间使用其它药物影响实验的疗效判定者。
(3)中途停止治疗者。
三、临床实验治疗方案
1.分组:随机数字表法分组,随机分为实验组1-3和对照组1-8。
实验组1:采用实施例1
实验组2:采用实施例2
实验组3:采用实施例3
对照组1:采用对比例1
对照组2:采用对比例2
对照组3:采用对比例3
对照组4:采用对比例4
对照组5:采用对比例5
对照组6:采用对比例6
对照组7:采用对比例7
对照组8:采用对比例8,即“糖尿通泥灸”
2.使用方法
(1)将实施例1-3或对比例1-8使用微波加热,加热时间为120s;
(2)将病灶处皮肤清洁干净,用灸油推按,热敷病灶处皮肤,待实施例1-3或对比例1-8的温度降至50℃以下后,涂覆于体表的胰岛部位、神阙穴、肾俞穴以及涌泉穴处;
(3)盖上塑料薄膜保温,60min后将人体皮肤表面洗净。
每两天使用一次,坚持使用180天。
四、疗效判定标准
1.疾病疗效判定标准
(1)显效。中医临床症状、体征明显改善;空腹血糖及餐后2小时血糖下降至正常范围,或空腹血糖及餐后2小时血糖值下降超过治疗前的40%,糖化血红蛋白值下降至6.2%以下,或下降超过治疗前的30%。
(2)有效。中医临床症状、体征均有好转;空腹血糖及餐后2小时血糖下降超过治疗前的20%,但未达到显效标准,糖化血红蛋白值下降超过治疗前的10%,但未达到显效标准。
(3)无效。空腹血糖及餐后2小时血糖无下降,或下降未达到有效标准,糖化血红蛋白值无下降,或下降未达到有效标准。
2.主要检测指标(血糖)疗效判定标准
(1)显效。空腹血糖及餐后2小时血糖下降至正常范围;或空腹血糖及餐后2小时血糖值下降超过治疗前的40%,糖化血红蛋白值下降至正常,或下降超过治疗前的30%。
(2)有效。空腹血糖及餐后2小时血糖下降超过治疗前的20%,但未达到显效标准,糖化血红蛋白值下降超过治疗前的10%,但未达到显效标准。
(3)无效。中医临床症状、体征均无明显改善,甚或加重;空腹血糖及餐后2小时血糖无下降,或下降未达到有效标准,糖化血红蛋白值无下降,或下降未达到有效标准。
注:空腹血糖、餐后2小时血糖应分别进行疗效评估。
3.证候疗效判定标准
(1)痊愈。中医临床症状、体征消失或基本消失。
(2)显效。中医临床症状、体征明显改善。
(3)有效。中医临床症状、体征均有好转。
(4)无效。中医临床症状、体征均无明显改善,甚或加重。
五、治疗结果
1.疾病疗效
组别 | 人数 | 显效 | 有效 | 无效 | 有效率 |
实验组1 | 100 | 42 | 51 | 7 | 93% |
实验组2 | 100 | 25 | 47 | 28 | 72% |
实验组3 | 100 | 27 | 42 | 31 | 69% |
对照组1 | 100 | 14 | 44 | 42 | 58% |
对照组2 | 100 | 12 | 36 | 52 | 48% |
对照组3 | 100 | 16 | 47 | 37 | 63% |
对照组4 | 100 | 13 | 53 | 34 | 66% |
对照组5 | 100 | 15 | 44 | 41 | 59% |
对照组6 | 100 | 4 | 38 | 58 | 42% |
对照组7 | 100 | 2 | 42 | 56 | 44% |
对照组8 | 100 | 3 | 31 | 66 | 34% |
2.血糖疗效
3.证候疗效
组别 | 人数 | 痊愈 | 显效 | 有效 | 无效 | 有效率 | 治愈率 |
实验组1 | 100 | 21 | 42 | 28 | 9 | 91% | 21% |
实验组2 | 100 | 6 | 48 | 29 | 17 | 83% | 6% |
实验组3 | 100 | 12 | 38 | 35 | 15 | 85% | 12% |
对照组1 | 100 | 0 | 5 | 59 | 36 | 64% | 0 |
对照组2 | 100 | 0 | 6 | 65 | 29 | 71% | 0 |
对照组3 | 100 | 0 | 18 | 49 | 33 | 67% | 0 |
对照组4 | 100 | 0 | 12 | 53 | 35 | 65% | 0 |
对照组5 | 100 | 0 | 16 | 46 | 38 | 62% | 0 |
对照组6 | 100 | 0 | 15 | 53 | 32 | 68% | 0 |
对照组7 | 100 | 0 | 10 | 55 | 35 | 65% | 0 |
对照组8 | 100 | 0 | 3 | 39 | 58 | 42% | 0 |
以上所述,仅为本发明的较佳实施例而已,并非用于限定本发明的保护范围。凡是根据本发明内容所做的均等变化与修饰,均涵盖在本发明的专利范围内。
Claims (10)
1.活力草本液,以重量份计,至少包含如下组分:
所述中草药混合物中各物质及其在中草药混合物中的重量份数为:
人参8-16份、黄芪2-10份、知母2-10份、栀子4-12份、石斛6-14份、黄精4-12份、枸杞6-14份、葛根8-16份、黄连10-18份、三七18-26份、厚朴1-8份、仙鹤草1-8份、虎杖2-10份、巴戟天4-12份、车前子8-16份、沉香14-22份、大豆20-28份、金刚刺31-39份、金樱根16-24份、金沙藤16-24份。
2.如权利要求1所述的活力草本液,其特征在于,所述中草药混合物中各物质及其在中草药混合物中的重量份数为:
人参10-14份、黄芪4-8份、知母4-8份、栀子6-10份、石斛8-12份、黄精6-10份、枸杞8-12份、葛根10-14份、黄连12-16份、三七20-24份、厚朴2-6份、仙鹤草2-6份、虎杖4-8份、巴戟天6-10份、车前子10-14份、沉香16-20份、大豆22-26份、金刚刺33-37份、金樱根18-22份、金沙藤18-22份。
3.如权利要求1所述的活力草本液,其特征在于,所述中草药混合物中各物质及其在中草药混合物中的重量份数为:
人参12份、黄芪6份、知母6份、栀子8份、石斛10份、黄精8份、枸杞10份、葛根12份、黄连14份、三七22份、厚朴4份、仙鹤草4份、虎杖6份、巴戟天8份、车前子12份、沉香18份、大豆24份、金刚刺35份、金樱根20份、金沙藤20份。
4.如权利要求1所述的活力草本液,其特征在于,所述托玛琳粉的粒径为200-10000目。
5.如权利要求1所述的活力草本液,其特征在于,所述陶瓷粉的粒径为80-1250 目。
6.如权利要求1所述的活力草本液,其特征在于,所述精油选自艾叶精油、薰衣草精油、玫瑰精油、甜橙精油、迷迭香精油、佛手柑精油、尤加利精油、雪松精油、葡萄柚精油、柠檬精油、依兰精油、洋甘菊精油中的至少一种。
7.如权利要求1所述的活力草本液,其特征在于,所述蜂蜡的酸值为4-9mgKOH/g,碘值为6-13g/100g,皂化值为75-100mg/g。
8.一种如权利要求1-7中任一项权利要求所述的活力草本液的使用方法,包括如下步骤:
(1)将所述活力草本液加热;
(2)将病灶处皮肤清洁干净,用灸油推按,热敷病灶处皮肤,待活力草本液温度降至50℃以下后,涂覆于病灶处皮肤表面;
(3)盖上塑料薄膜保温,30-75min后将人体皮肤表面洗净。
9.如权利要求8所述的使用方法,其特征在于,所述加热为微波加热,加热时间为90-210s。
10.如权利要求1-7中任一项权利要求所述的活力草本液在化妆品、外敷药、外敷保健品领域中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610554198.7A CN106177659A (zh) | 2016-07-14 | 2016-07-14 | 活力草本液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610554198.7A CN106177659A (zh) | 2016-07-14 | 2016-07-14 | 活力草本液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106177659A true CN106177659A (zh) | 2016-12-07 |
Family
ID=57474330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610554198.7A Pending CN106177659A (zh) | 2016-07-14 | 2016-07-14 | 活力草本液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106177659A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112494359A (zh) * | 2020-12-15 | 2021-03-16 | 广州市尚梓化工科技有限公司 | 一种海藻寡糖的制备方法及在抗衰老化妆品的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103251867A (zh) * | 2013-06-03 | 2013-08-21 | 滕信涛 | 一种治疗糖尿病的中药复方药物及其制备方法 |
CN103638395A (zh) * | 2013-12-19 | 2014-03-19 | 青岛友铭辰生物技术有限公司 | 一种调节血糖中药片剂及其制备方法 |
CN103784802A (zh) * | 2014-02-28 | 2014-05-14 | 杨月生 | 一种治疗糖尿病的中药组合物 |
CN104352942A (zh) * | 2014-11-26 | 2015-02-18 | 杨其义 | 一种治疗糖尿病的中药组合物 |
CN105327181A (zh) * | 2015-12-03 | 2016-02-17 | 济南星懿医药技术有限公司 | 一种治疗糖尿病的药物组合物 |
-
2016
- 2016-07-14 CN CN201610554198.7A patent/CN106177659A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103251867A (zh) * | 2013-06-03 | 2013-08-21 | 滕信涛 | 一种治疗糖尿病的中药复方药物及其制备方法 |
CN103638395A (zh) * | 2013-12-19 | 2014-03-19 | 青岛友铭辰生物技术有限公司 | 一种调节血糖中药片剂及其制备方法 |
CN103784802A (zh) * | 2014-02-28 | 2014-05-14 | 杨月生 | 一种治疗糖尿病的中药组合物 |
CN104352942A (zh) * | 2014-11-26 | 2015-02-18 | 杨其义 | 一种治疗糖尿病的中药组合物 |
CN105327181A (zh) * | 2015-12-03 | 2016-02-17 | 济南星懿医药技术有限公司 | 一种治疗糖尿病的药物组合物 |
Non-Patent Citations (1)
Title |
---|
心想事自成: "蜡泥配方", 《HTTP://WWW.360DOC.COM/CONTENT/15/0904/23/7587352_496933577.SHTML》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112494359A (zh) * | 2020-12-15 | 2021-03-16 | 广州市尚梓化工科技有限公司 | 一种海藻寡糖的制备方法及在抗衰老化妆品的应用 |
CN112494359B (zh) * | 2020-12-15 | 2021-08-31 | 广州市尚梓化工科技有限公司 | 一种海藻寡糖的制备方法及在抗衰老化妆品的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102091258B (zh) | 一种祛除疤痕的中药组合物及其制备方法 | |
CN103520578A (zh) | 一种治疗口腔溃疡的中药组合物及其制备方法 | |
CN103432475B (zh) | 一种治疗过敏性鼻炎的中药组合物及其制备方法 | |
CN103768567B (zh) | 一种黑膏药及其制备方法 | |
CN103520694B (zh) | 治疗慢性阻塞性肺病稳定期的中药组合物及其制备方法 | |
CN103638250B (zh) | 一种治疗面神经麻痹的中药制剂及其制备方法 | |
CN104288609A (zh) | 一种治疗胃火炽盛型牙龈炎的中药组合物及其制备方法 | |
CN105267747A (zh) | 一种治疗糖尿病的中药组合物、制剂及其制备方法 | |
CN103520655B (zh) | 一种治疗寻常型银屑病的中药组合物及其制备方法 | |
CN104069474A (zh) | 一种治疗脂溢性脱发的中药组合物及其制备方法 | |
CN104522213A (zh) | 适宜三高人群饮用的茶饮及其制备方法 | |
CN106491804A (zh) | 一种桶药浴之瑶娃娃浴粉及其制备方法 | |
CN105878776A (zh) | 治疗颈肩腰腿病的药物组合物、制剂及其制备方法和应用 | |
CN104147460A (zh) | 一种治疗帕金森病的中药制剂及其制备方法 | |
CN105997737A (zh) | 吕透净化草本膜 | |
CN106177659A (zh) | 活力草本液 | |
CN102579818A (zh) | 一种藏药组合物及其制备方法与应用 | |
CN112494614A (zh) | 一种木瓜百药组合防治癌病的中药配方 | |
CN105816760A (zh) | 一种活血化瘀、定痛止血、殓疮生肌、消炎止痛的膏药及其制备方法 | |
CN101897733A (zh) | 一种治疗膀胱结石的药物及其制备方法 | |
CN104997956A (zh) | 贝赛特氏综合症及其治疗药物 | |
CN104689283A (zh) | 一种治疗脾虚湿蕴型黄褐斑的药物及其制备方法 | |
CN104623532A (zh) | 一种治疗脑胶质瘤的中药组合物及其制备方法 | |
CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
CN106511922A (zh) | 一种桶药浴之经络发热药油制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 450000 Henan Zhengzhou City Henan Free Trade Experimental Zone Zhengzhou District (Zhengdong) Business Outer Ring Road 29 Cathay Pacific Wealth Center 2201 Applicant after: ZHENGZHOU WUXING SHUTI TECHNOLOGY CO.,LTD. Address before: Room 815, D Block, Centennial Dehua, Erqi District, Zhengzhou City, Henan Province, 450000 Applicant before: ZHENGZHOU WUXINGSHUTI COMMERCE AND TRADE CO.,LTD. |
|
CB02 | Change of applicant information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161207 |
|
RJ01 | Rejection of invention patent application after publication |